Published in J Alzheimers Dis on February 01, 2001
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol (2001) 1.69
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab (2013) 1.45
Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.42
beta-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol (2006) 1.35
Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci U S A (2013) 1.21
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol (2016) 0.98
The role of inflammatory processes in Alzheimer's disease. Inflammopharmacology (2012) 0.92
Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer's disease. Front Cell Neurosci (2015) 0.90
Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J Neurosci (2008) 0.87
Why AMD is a disease of ageing and not of development: mechanisms and insights. Front Aging Neurosci (2014) 0.84
High levels of homocysteine results in cerebral amyloid angiopathy in mice. J Alzheimers Dis (2015) 0.79
Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice. Mol Neurodegener (2015) 0.79
Multi-Kernel Classification for Integration of Clinical and Imaging Data: Application to Prediction of Cognitive Decline in Older Adults. Med Image Comput Comput Assist Interv (2011) 0.78
Effects of apoE deficiency and occlusal disharmony on amyloid-beta production and spatial memory in rats. PLoS One (2013) 0.78
Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding. Fluids Barriers CNS (2016) 0.75
Transnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice. BMC Neurosci (2016) 0.75
A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J (2002) 3.87
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol (2010) 2.42
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J (2007) 1.97
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus. Blood (2010) 1.47
Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. J Biol Chem (2007) 1.44
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci (2004) 1.43
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci (2006) 1.38
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med (2004) 1.37
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
Immunization delays the onset of prion disease in mice. Am J Pathol (2002) 1.26
Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis (2002) 1.24
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci (2006) 1.22
An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates. J Virol (2005) 1.22
Copper chelation delays the onset of prion disease. J Biol Chem (2003) 1.17
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol (2007) 1.15
Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res (2004) 1.11
Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett (2003) 1.09
Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res (2004) 1.08
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol (2002) 1.07
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol (2007) 1.06
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol (2012) 1.02
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol (2004) 1.01
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol (2006) 1.01
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol (2008) 1.00
Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis (2009) 1.00
Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice. J Virol (2008) 0.99
Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage (2011) 0.98
Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. J Virol (2005) 0.95
Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis (2011) 0.94
Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J Neuropathol Exp Neurol (2004) 0.94
Infectivity of amyloid diseases. Trends Mol Med (2002) 0.93
Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. Int J Alzheimers Dis (2012) 0.93
A safer vaccine for Alzheimer's disease? Neurobiol Aging (2002) 0.93
Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: implications for cellular Aβ metabolism. Biochim Biophys Acta (2011) 0.93
The innate immune system in Alzheimer's disease. Int J Cell Biol (2013) 0.92
Targeting prion amyloid deposits in vivo. J Neuropathol Exp Neurol (2004) 0.91
Disease modifying approaches for Alzheimer's pathology. Curr Pharm Des (2007) 0.90
Stereological study of the neuronal number and volume of 38 brain subdivisions of subjects diagnosed with autism reveals significant alterations restricted to the striatum, amygdala and cerebellum. Acta Neuropathol Commun (2014) 0.90
Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine (2008) 0.90
Abnormal intracellular accumulation and extracellular Aβ deposition in idiopathic and Dup15q11.2-q13 autism spectrum disorders. PLoS One (2012) 0.89
Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scrapie prion. J Neurochem (2004) 0.89
Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques. Chembiochem (2007) 0.89
Magnetic resonance imaging of amyloid plaques in transgenic mice. Methods Mol Biol (2005) 0.88
Differences between the pattern of developmental abnormalities in autism associated with duplications 15q11.2-q13 and idiopathic autism. J Neuropathol Exp Neurol (2012) 0.88
Neuronal nucleus and cytoplasm volume deficit in children with autism and volume increase in adolescents and adults. Acta Neuropathol Commun (2015) 0.87
Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology. J Neurochem (2013) 0.87
In vivo micro magnetic resonance imaging signal changes in scrapie infected mice. Neurosci Lett (2003) 0.86
Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PLoS One (2013) 0.86
Prevalence of dementia and main subtypes in rural northern China. Dement Geriatr Cogn Disord (2015) 0.85
Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol (2011) 0.85
Contribution of olivofloccular circuitry developmental defects to atypical gaze in autism. Brain Res (2013) 0.85
Tau-based therapeutic approaches for Alzheimer's disease - a mini-review. Gerontology (2014) 0.85
Prevalence of cognitive impairment no dementia in a rural area of Northern China. Neuroepidemiology (2014) 0.85
Promising developments in prion immunotherapy. Expert Rev Vaccines (2005) 0.83
Styryl-based and tricyclic compounds as potential anti-prion agents. PLoS One (2011) 0.83
Chemical Fluorescent Probe for Detection of Aβ Oligomers. J Am Chem Soc (2015) 0.83
A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. J Alzheimers Dis (2004) 0.83
Test for detection of disease-associated prion aggregate in the blood of infected but asymptomatic animals. Clin Vaccine Immunol (2006) 0.82
Brain-region-specific alterations of the trajectories of neuronal volume growth throughout the lifespan in autism. Acta Neuropathol Commun (2014) 0.82
Substrate determinants in the C99 juxtamembrane domains differentially affect γ-secretase cleavage specificity and modulator pharmacology. J Neurochem (2013) 0.82
Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cell Immunol (2010) 0.81
Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain (2014) 0.81
In vivo magnetic resonance imaging of amyloid-β plaques in mice. Methods Mol Biol (2012) 0.80
Clearance systems in the brain-implications for Alzheimer diseaser. Nat Rev Neurol (2016) 0.80
Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine. J Alzheimers Dis (2009) 0.80
Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cell Immunol (2011) 0.79
Vaccines for conformational disorders. Expert Rev Vaccines (2004) 0.79
Influence of Mabs on PrP(Sc) formation using in vitro and cell-free systems. PLoS One (2012) 0.78
An entorhinal cortex sulcal pattern is associated with Alzheimer's disease. Hum Brain Mapp (2009) 0.78
Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation. Cogn Behav Neurol (2008) 0.78
Mechanistic insights into the cure of prion disease by novel antiprion compounds. J Virol (2007) 0.77
Apolipoprotein Ε ε4 frequency is increased among Chinese patients with frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord (2013) 0.77
Diaryl substituted pyrazoles as potent CCR2 receptor antagonists. Bioorg Med Chem Lett (2006) 0.76
State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major depression. Neuroreport (2016) 0.75
An animal model of vascular amyloidosis. Nat Neurosci (2004) 0.75
Dissolution of pre-existing platelet thrombus by synergistic administration of low concentrations of bifunctional antibodies against β3 integrin. PLoS One (2011) 0.75
Role of CD40 in prion disease and the immune response to recombinant PrP. J Neuroimmunol (2013) 0.75
Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0. J Biomol Screen (2012) 0.75